Please assess the completion status of the following clinical trial:

Trial Title: PCV10 Immunogenicity Study Nepal 2015

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female, aged 40-60 days at time of first study vaccination~* Parent/ guardian of participant is willing and able to give informed consent for participation in the study.~* In good general health as determined by:~  * medical history~ * physical examination~ * clinical judgment of the investigator~* Participants residing in Kathmandu~* Parents able (in the Investigators opinion) and willing to comply with all study requirements.~Exclusion Criteria:~* Parent/guardian unwilling or unable to give written informed consent to participate in the study~* Previous immunisation (excluding BCG, OPV, hepatitis B, measles or other government vaccine programme) or planned vaccination during the study period with vaccine not foreseen by this study protocol except influenza vaccine and oral polio vaccination as recommended locally.~* Premature birth (\<37 weeks gestation)~* Previous hospital admission except where hospital stay would not compromise the study in the judgment of the investigator.~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.~* Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the vaccination, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- 6 + 10 weeks of age PCV10 priming (Type: ACTIVE_COMPARATOR): 10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
- 6 + 14 weeks of age PCV10 priming (Type: ACTIVE_COMPARATOR): 10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).